Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...
ThePrint on MSN1d
PGIMER report bats for new-age targeted lung cancer therapies to be included in AB-PMJAYReport commissioned by govt analysed cost-effectiveness of 2 medicines, comparing them to to chemo in patients with newly ...
Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...
Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.
An application was submitted to the European Medicines Agency seeking approval for treatment with sugemalimab in stage 3 ...
Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication. Alecensa ...
Olverembatinib (HQP1351), a novel, next-generation TKI and the first third-generation BCR-ABL1 TKI, has been approved in ...
Teacher Retirement System of Texas lifted its stake in shares of Nuvalent, Inc. (NASDAQ:NUVL – Free Report) by 43.1% during the fourth quarter, according to its most recent disclosure with the ...
CStone Pharma seeks EMA approval for sugemalimab to treat patients with unresectable stage III non-small cell lung cancer: Suzhou, China Tuesday, March 25, 2025, 17:00 Hrs [IST] C ...
Researchers have initiated a phase 2 trial assessing a novel tyrosine kinase inhibitor that can potentially penetrate the central nervous system in patients with ALK-positive non-small cell lung ...
A phase 3 trial – called TeliMET-NSCLC-01 ... in c-Met-positive, non-squamous NSCLC, in patients both with and without other gene mutations including EGFR and ALK. Other drugmakers have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback